Injective Drops 10% as Broad Altcoin Selloff Hits Layer-1 DeFi Tokens
Injective fell 10.4% in the 24 hours to May 14, sliding to $5.05 as a broad altcoin selloff swept DeFi-focused layer-1 tokens. The decline cut Injective’s market cap to $504 million and pushed daily trading volume to $405 million.
Bitcoin held near $79,800 during the same period, keeping pressure on risk assets across the cryptocurrency market.
The Sell Pressure Behind INJ’s Drop
The Injective price drop mirrors losses across the altcoin tier. Venice Token (VVV) fell 8.1%, Billions Network (BILL) lost 16.4%, and the broader crypto market showed risk-off behavior as macro caution weighed on sentiment. Bitcoin’s inability to reclaim $82,000 after four failed attempts has compressed the appetite for higher-risk altcoin positions.
Injective’s 24-hour volume of $405 million is notable against its $504 million market cap.
A volume-to-market-cap ratio above 0.8 often signals elevated speculative activity. Traders cycling in and out of short positions can amplify price moves in either direction.
The data does not confirm whether selling pressure came from spot liquidations or from derivatives markets, but the magnitude of the drop across multiple DeFi layer-1 tokens suggests sector-wide rotation rather than Injective-specific news.
Also Read: Jupiter Holds Rank 86 as Solana’s Largest DEX Aggregator Weathers Broad Market Weakness
Background
Injective is a layer-1 blockchain purpose-built for decentralized finance applications. It is designed to support on-chain order books, derivatives trading, and cross-chain liquidity across multiple networks.
The protocol uses a proof-of-stake consensus mechanism, where validators lock up the native INJ token to secure the network and earn rewards. Injective ranks 106th by market cap among all cryptocurrencies.
The token’s price history reflects the wider altcoin cycle.
INJ reached highs above $40 during the late 2023 bull run before declining sharply through 2024 and into 2025. The token traded in the $4 to $7 range through much of early 2026 as institutional interest concentrated in Bitcoin and Ethereum (ETH) rather than smaller layer-1 alternatives.
The May 14 drop to $5.05 keeps INJ near the lower end of that 2026 range.
Layer-1 blockchains with DeFi-focused positioning have faced sustained competition from layer-2 networks, which are secondary blockchain networks built on top of existing chains like Ethereum that offer lower transaction fees and faster settlement. As layer-2 activity grows, some capital that previously flowed to competing layer-1 chains has redirected toward Ethereum-adjacent ecosystems instead.
Also Read: UK Economy Beats Forecasts With 0.6% Q1 Growth Despite Iran War Headwinds
What the Volume Data Shows
The $405 million in daily volume against a $504 million market cap places Injective among the more actively traded mid-cap tokens.
High turnover can indicate speculative short-term positioning rather than long-term accumulation. Traders watching the INJ chart on May 14 saw a token that had failed to hold the $5.50 support level.
The next significant technical area sits near $4.50, which represented a consolidation zone in late 2025.
The broader altcoin market context matters here. When Bitcoin dominance remains elevated, typically above 55%, altcoin markets tend to underperform.
Bitcoin dominance was holding above that threshold in mid-May 2026, meaning Bitcoin controlled a larger share of total crypto market value than at most points in the prior two years. That dynamic discourages rotation into altcoins and can extend selling periods.
Also Read: Billions Network Draws $890 Million in Daily Volume Despite a Market Cap of $411 Million
Outlook for INJ
Injective’s short-term price path depends heavily on whether Bitcoin can stabilize above $79,000.
A sustained break below that level would likely extend altcoin losses, while a recovery toward $82,000 could trigger a bounce in DeFi-focused tokens. Traders will watch whether the $5.00 psychological level holds as a floor for INJ.
Protocol-level developments, such as new DeFi application launches or cross-chain integrations, could provide a demand catalyst independent of broader market conditions. Neither Injective’s core team nor its validators have issued statements addressing the May 14 price move.
Read Next: US Army Recovers Body of Second Soldier Missing in Morocco
